AUG 22, 2018 9:43 PM PDT

New Clinical Assay Useful For Urothelial Cancer

WRITTEN BY: Nouran Amin

U.S. Food and Drug Administration (FDA) has now approved a pharmDx assay called ‘Dako PD-L1 IHC 22C3’ by Agilent Technologies Inc. for use in urothelial carcinoma. The assay is the only approved companion diagnostic to help identify patients with urothelial carcinoma for treatment with KEYTRUDA, which is a monoclonal anti-PD1 therapy manufactured by the pharmaceutical company known Merck for the first-line treatment option of cancer.

Specifically, KEYTRUDA is approved for cancer patients experiencing locally advanced or metastatic urothelial carcinoma and who are not eligible for cisplatin-containing chemotherapy. Additionally, their tumors must express PD-L1 [Combined Positive Score (CPS) ≥ 10] as determined through an FDA-approved test, or in patients who are not eligible for any platinum-containing chemotherapy.

The pharmDx assay referred to as ‘PD-L1 IHC 22C3’ follows previous FDA-approved assay for non-small cell lung cancer (NSCLC), gastric or gastroesophageal junction (GEJ) adenocarcinoma, and cervical cancer. "Anti-PD-1 therapies are a promising treatment class for many cancer types, and early PD-L1 testing can provide critical information to physicians managing urothelial carcinoma patients," explains Sam Raha, the president of Agilent's Diagnostics and Genomics Group. "By expanding the use of PD-L1 IHC 22C3 pharmDx, Agilent strives to address the unmet need for treatment options in patients who are ineligible for cisplatin-containing chemotherapy. Through these efforts, we maintain our commitment to bringing companion diagnostics to the market in support of groundbreaking immuno-oncology therapeutics."

The 5th most common cancer in the United States, urothelial carcinoma holds an estimated incidence of 81,000 new diagnoses in just 2018. For 30 years, cancer-related morality has not approved for patients with advanced/metastatic urothelial carcinoma with a five-year survival rate of approximately 15%. Additionally, the age along with disease-associated comorbidities affect patient eligibility for standard treatments such as cisplatin-containing chemotherapy. Patients that cannot be administered cisplatin-containing chemotherapy, will have an unmet need for effective therapy.

Source: Agilent

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
MAY 24, 2021
Clinical & Molecular DX
Discovery of Viral Peptides Paves the Way for Cheaper, More Accurate COVID Diagnostics
MAY 24, 2021
Discovery of Viral Peptides Paves the Way for Cheaper, More Accurate COVID Diagnostics
Over 1.5 billion vaccine doses have been administered worldwide, but SARS-CoV-2 variants are now threatening efforts to ...
JUN 24, 2021
Clinical & Molecular DX
Test Lets Cancer Patients Track Whether Their Treatment Is Working in Real Time
JUN 24, 2021
Test Lets Cancer Patients Track Whether Their Treatment Is Working in Real Time
Researchers from Singapore have created the ExoSCOPE, the world’s first blood test for tracking whether or not a p ...
JUN 30, 2021
Clinical & Molecular DX
A Deep Learning Tool for Faster, Better Heart Disease Diagnoses
JUN 30, 2021
A Deep Learning Tool for Faster, Better Heart Disease Diagnoses
A new deep learning tool could help slash the time it takes to interpret cardiology scans to diagnose obstructive corona ...
JUL 15, 2021
Technology
Raman Spectroscopy Helps Track IBD Patient Response to Treatment
JUL 15, 2021
Raman Spectroscopy Helps Track IBD Patient Response to Treatment
While there have been multiple methods of evaluating whether a patient with inflammatory bowel disease (IBD) is respondi ...
JUL 29, 2021
Genetics & Genomics
Obesity May Not Always Lead to Disease
JUL 29, 2021
Obesity May Not Always Lead to Disease
Some gene variants might be protecting people from the negative health effects of obesity.
SEP 05, 2021
Microbiology
Gut Bacteria May Influence Infant Brain Development
SEP 05, 2021
Gut Bacteria May Influence Infant Brain Development
Our health is closely connected to the community of microbes we carry in our gut. For example, these microbes have a pow ...
Loading Comments...